Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-801 Monotherapy and Combination With Pembrolizumab in Advanced Solid Tumors
NCT06462794Phase 1Recruiting
- Sponsor
- CytomX
- Start
- Aug 2024
- Primary completion
- Feb 2028
- Modality
- Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of CX-801 in solid tumor (2 arms), sponsored by CytomX. Primary endpoints: Safety and tolerability of CX-801 as monotherapy and combination therapy at 44 months and Recommended Phase 2 dose at 44 months. Started Aug 2024; status: recruiting.
02
Drugs
CX-801
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06462794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462794.